Protalix Biotherapeutics Key Fundamental Indicators

Protalix Biotherapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 52.1 M 84.4 M 69.4 M Pretty Stable Total Current Liabilities 20.5 M 29.5 M 31.6 M Slightly volatile Cash 31.4 M 22.7 M 37.6 M Slightly volatile Non Current Assets Total 9.8 M 15.3 M 12.1 M Very volatile Cash And Short Term Investments 33.8 M 40.1 M 42.4 M Pretty Stable Net Receivables 2.9 M 3.3 M 2.9 M Slightly volatile Common Stock Shares Outstanding 97.9 M 93.2 M 33.8 M Slightly volatile Liabilities And Stockholders Equity 52.1 M 84.4 M 69.4 M Pretty Stable Non Current Liabilities Total 5 M 5.3 M 47 M Slightly volatile Other Current Assets 1.6 M 986.4 K 2.1 M Slightly volatile Total Liabilities 55.3 M 34.7 M 80.3 M Slightly volatile Total Current Assets 43.3 M 69.1 M 57.3 M Pretty Stable Short and Long Term Debt Total 4.7 M 5 M 44.9 M Slightly volatile Property Plant And Equipment Net 10.5 M 11.5 M 10.4 M Very volatile Non Currrent Assets Other 504.7 K 531.3 K 2.4 M Slightly volatile Common Stock Total Equity 62.7 K 40.2 K 69.1 K Slightly volatile Other Stockholder Equity 509 M 484.8 M 314.9 M Slightly volatile Common Stock 63.6 K 87.4 K 78.4 K Very volatile Accounts Payable 4.1 M 5.2 M 5.4 M Very volatile Short Term Investments 18.2 M 17.3 M 8.2 M Slightly volatile Other Assets 4 M 3.8 M 1.7 M Slightly volatile Other Liabilities 1.4 M 1.5 M 18.8 M Slightly volatile Property Plant Equipment 8.2 M 9 M 9.9 M Pretty Stable Current Deferred Revenue 3.1 M 3.3 M 7.6 M Pretty Stable Inventory 25.7 M 24.4 M 11.4 M Slightly volatile Capital Surpluse 298.9 M 484.8 M 278.4 M Slightly volatile Non Current Liabilities Other 43.6 K 45.9 K 28.3 M Slightly volatile Short and Long Term Debt 34.9 M 18.2 M 39.3 M Slightly volatile Deferred Long Term Asset Charges 101.6 K 101.7 K 118.3 K Slightly volatile Property Plant And Equipment Gross 55.3 M 52.6 M 22.8 M Slightly volatile Cash And Equivalents 22.5 M 17.8 M 36.6 M Slightly volatile Capital Stock 51.1 K 68.4 K 103 K Slightly volatile Capital Lease Obligations 4.5 M 5 M 5.6 M Slightly volatile
Protalix Biotherapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Selling General Administrative 49.3 M 46.9 M 15.1 M Slightly volatile Other Operating Expenses 32.3 M 56.9 M 46.4 M Slightly volatile Total Operating Expenses 25 M 28.9 M 34.5 M Pretty Stable Depreciation And Amortization 1.6 M 1.5 M 1.9 M Slightly volatile Total Revenue 64.5 M 61.4 M 35 M Slightly volatile Gross Profit 35.1 M 33.4 M 21.3 M Slightly volatile Cost Of Revenue 29.4 M 28 M 13.3 M Slightly volatile Research Development 27 M 14.9 M 26.3 M Very volatile Selling And Marketing Expenses 64 M 60.9 M 21.6 M Slightly volatile Extraordinary Items 29.6 K 33.3 K 36.3 K Slightly volatile Interest Income 768.8 K 1.5 M 711 K Slightly volatile Reconciled Depreciation 1.1 M 1.2 M 1.6 M Slightly volatile
Protalix Biotherapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 30.8 M 27.2 M 38.7 M Pretty Stable End Period Cash Flow 31.4 M 22.7 M 37.6 M Slightly volatile Depreciation 2 M 1.5 M 2 M Slightly volatile Stock Based Compensation 2.3 M 2.9 M 2.4 M Pretty Stable Issuance Of Capital Stock 3.1 M 3.3 M 35.1 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 2.79 2.94 72.9603 Slightly volatile Days Sales Outstanding 21.72 22.87 33.9354 Slightly volatile Average Payables 45.2 K 47.6 K 49.2 K Slightly volatile Stock Based Compensation To Revenue 0.0666 0.0701 1.4439 Slightly volatile Capex To Depreciation 1.21 1.13 0.7182 Slightly volatile EV To Sales 2.5 2.63 72.7311 Slightly volatile Inventory Turnover 1.8 1.32 1.6283 Slightly volatile Days Of Inventory On Hand 501 367 453 Very volatile Payables Turnover 5.07 4.83 2.8818 Slightly volatile Research And Ddevelopement To Revenue 0.27 0.28 2.7338 Slightly volatile Capex To Revenue 0.0262 0.0276 0.0828 Slightly volatile Cash Per Share 0.52 0.55 1.475 Slightly volatile Days Payables Outstanding 74.33 78.24 317 Slightly volatile Current Ratio 2.56 2.7 7.6103 Slightly volatile Receivables Turnover 17.35 16.52 13.3288 Slightly volatile Graham Number 1.17 0.85 1.1575 Slightly volatile Capex Per Share 0.0193 0.0203 0.0559 Slightly volatile Revenue Per Share 0.8 0.85 2.1711 Slightly volatile Interest Debt Per Share 0.0777 0.0817 1.2609 Very volatile Debt To Assets 0.0644 0.0677 0.5717 Slightly volatile Operating Cycle 370 390 471 Very volatile Days Of Payables Outstanding 74.33 78.24 317 Slightly volatile Quick Ratio 1.66 1.74 7.2268 Slightly volatile Cash Ratio 0.84 0.89 2.0715 Slightly volatile Days Of Inventory Outstanding 501 367 453 Very volatile Days Of Sales Outstanding 21.72 22.87 33.9354 Slightly volatile Fixed Asset Turnover 5.04 4.8 3.8216 Slightly volatile Debt Ratio 0.0644 0.0677 0.5717 Slightly volatile Price Sales Ratio 2.79 2.94 72.9603 Slightly volatile Asset Turnover 0.59 0.84 0.5897 Pretty Stable Gross Profit Margin 0.51 0.49 0.5289 Slightly volatile
Protalix Biotherapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 72.5 M 76.4 M 648.4 M Slightly volatile Enterprise Value 1.2 B 867.5 M 1.2 B Slightly volatile

Protalix Fundamental Market Drivers

Protalix Upcoming Events

Protalix Return On Equity Driver Correlations

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details

Protalix Biotherapeutics 'What if' Analysis

Hype Prediction Low Estimated High 0.15 3.03 6.79 Details

Intrinsic Valuation Low Real High 1.08 4.83 8.59 Details

1 Analysts Consensus Low Target High 10.01 11.00 12.21 Details

Earnings Estimates (0) Low Projected EPS High -0.01 0.02 0.05 Details

Protalix Biotherapeutics February 13, 2026 Technical Indicators

Protalix Biotherapeutics Backtested Returns

Competition

Predict Protalix Biotherapeutics

Return On Equity Over Time

Protalix Liabilities And Stockholders Equity

Protalix Biotherapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Protalix Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Protalix Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protalix Biotherapeutics competition to find correlations between indicators driving Protalix Biotherapeutics's intrinsic value. More Info.Protalix Biotherapeutics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about  0.44  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Protalix Biotherapeutics is roughly  2.29 . At this time, Protalix Biotherapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protalix Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Protalix Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.

Protalix Biotherapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protalix Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protalix Biotherapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Protalix Fundamentals

About Protalix Biotherapeutics Fundamental Analysis

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protalix Stock Analysis